Загрузка...
Weekly EZN-2208 (PEGylated SN-38) in combination with bevacizumab in patients with refractory solid tumors
BACKGROUND: Anti-angiogenic therapies such as bevacizumab upregulate hypoxia-inducible factor-1α (HIF-1α), a possible mechanism of drug resistance. Camptothecin analogues, including SN-38, have been shown to reduce the expression and transcriptional activity of HIF-1α in preclinical models. We hypot...
Сохранить в:
| Опубликовано в: : | Invest New Drugs |
|---|---|
| Главные авторы: | , , , , , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2013
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7670584/ https://ncbi.nlm.nih.gov/pubmed/24242862 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-013-0048-3 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|